- Major biotechnology reagent company in a multiple jurisdiction patent infringement case involving biotech tools for genetic engineering - Major seed company as plaintiff in connection with six related transgenic corn technology litigations industry in multiple jurisdictions involving the entire corn seed industry - Leading biotechnology reagent and device company in multiple merger and buy-out due diligences Guided a leading biopharmaceutical company in patent-related aspects of its biological licensure application (BLA) to the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) - Manages and oversees the patent portfolio of numerous universities, biopharmaceutical research organizations and companies and a front-line pluripotent stem cell company Obtained a substantial settlement as lead litigation counsel representing a major university in a patent infringement action involving pharmaceutical products - Major university in a patent infringement action involving pet food flavoring agents - Major biopharmaceutical company as plaintiff and defendant in related patent infringement cases involving one of the first biopharmaceutical products - U.S. counsel in successfully defending a leading biopharmaceutical company in six European oppositions and appeals before the Technical Board of Appeals of the EPO involving related biopharmaceutical patents - Twice received a favorable ruling from the Court of Appeals for the Federal Circuit in Brown v. Barbacid, a seminal interference matter representing Nobel laureates and their technology directed to an important new class of cancer therapeutics - Major cancer research and treatment center in Federal District Court and before the Court of Appeals for the Federal Circuit in obtaining a dismissal of a patent and contract matter under the 11th Amendment to the Constitution

I moved from Arnold, White & Durkee to Fulbright & Jaworksi with most of the AWD Austin group in February, 2000. I began my career at Fulbright as head of the IPT (Intellectual Property and Technology) Section and, in 2008, became Co-Chair of the IPT Section firmwide. On August 1, 2012, I, together with Drs. Steve Highlander and Mark Voges, opened Parker Highlander PLLC, with 10 employees, a firm specializing in all phases of life science intellectual property work.